OncoMed Announces First Quarter 2018 Financial Results and Operational Highlights

OncoMed Pharmaceuticals (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced first quarter 2018...

8 Glioblastoma Treatment Stocks

With an average survival rate of 16 months, glioblastoma is the most common and deadly type of brain cancer, accounting...

5 Top Weekly NASDAQ Biotech Stocks: Eleven Biotherapeutics Up 45 Percent

Eleven Biotherapeutics, EyePoint Pharmaceuticals, Avid Bioservices, Cerecor and Celldex were last week's top gainers on the NASDAQ.

Calithera Biosciences Announces FDA Fast Track Designation Granted to CB-839

Calithera Biosciences (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer therapeutics, today announced that the...

Tyme Provides Clinical and Corporate Update for Fiscal Year End 2018

Tyme Technologies (NASDAQ:TYME), a clinical-stage oncology company developing metabolically-based cancer therapeutics, today announced a clinical and corporate update for the...

5 Top NASDAQ Biotech Stocks: Cardiome on Top

Cardiome, Avid, XBiotech, Fennec and Compugen were last week's five top-gaining NASDAQ biotech stocks. See what moved their share prices.

5 Top NASDAQ Biotech Stocks: Second Sight Medical on Top

Second Sight, Juniper, Athersys, Aptose and ArQule were last week's five top-gaining NASDAQ biotech stocks. See what moved their share...